New cocktail therapy aims to shrink Hard-to-Treat tumors
NCT ID NCT07327411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial will test a combination of four treatments—cetuximab β (a targeted antibody), radiation, an immunotherapy drug (envafolimab), and a growth factor (GM-CSF)—in 40 adults with advanced solid tumors that have EGFR protein and are no longer responding to standard care. The goal is to see if this mix can shrink tumors or slow disease progression. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cetuximab β (anti-EGFR antibody) combined with hypofractionated radiotherapy, envafolimab (PD-L1 inhibitor), and GM-CSF
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a small, early-phase trial (40 people) with no control group, so results may not apply broadly. The combination also carries risks of side effects from radiation and immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED REFRACTORY SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215163, China
Contact Phone: •••-•••-•••• Email: •••••@•••••